FLAG-IDA Plus Venetoclax Performs Well in Children, AYA with Newly Diagnosed AML
The combination of fludarabine, cytarabine, granulocyte colony-stimulating factor, and idarubicin (FLAG-IDA) plus venetoclax appeared to be a highly effective treatment regimen in ...
ASAP Trial Challenges Standard Practice of Remission Induction Before Transplant in AML
Despite widespread clinical adoption, the practice of inducing complete remission (CR) before allogeneic hematopoietic cell transplantation ...
Intermediate Dose of Cytarabine as Effective as Higher Dose for Post-Induction in AML
Thirty years ago, a seminal report by the Cancer and Leukemia Group established repeated courses of high-dose cytarabine (HDAC) as a good post-remission treatment option for patients with ...
p53 IHC Testing May Be Reliable Surrogate for Early Identification of TP53-Mutated MDS, AML
p53 immunohistochemistry (IHC) may be a useful and timely surrogate testing method for early characterization of TP53-mutated myelodysplastic syndromes (MDS) and acute myeloid leukemia ...
Revumenib Looks to Fill a Therapeutic Void for Patients With R/R NPM1-Mutated AML
AUGMENT-101 was a phase I/II dose-escalation and expansion study testing revumenib in patients age 30 or older with R/R KMT2A-rearranged acute leukemia or NPM1-mutated AML ...
Menin Inhibitor Revumenib Yields Clinically Meaningful Responses in R/R NPM1-Mutated AML
Treatment with the menin inhibitor revumenib yielded “clinically meaningful” responses in patients with relapsed or refractory acute myeloid leukemia (R/R AML) with an NPM1 mutation ...
Phase II Results Point Toward a New Era in Treating Acute Myeloid Leukemia
Results from the phase II cohort of a trial evaluating the all-oral regimen of decitabine-cedazuridine (DEC-C) plus venetoclax (VEN) in patients with acute myeloid leukemia (AML) who are ...
Magrolimab Plus Azacitidine Did Not Improve Outcomes in TP53-Mutated AML
The combination of CD47-targeting magrolimab plus azacitidine did not improve survival compared with physician’s choice of treatment in patients with TP53-mutated acute myeloid leukemia ...
Venetoclax Plus Decitabine Shows Similar Efficacy to Intensive Chemotherapy as Front- Line Therapy for Young, Fit Patients With AML
The combination of venetoclax plus decitabine is shown to be as effective and have a better safety profile when compared with the current chemotherapy-based standard of care ...
Final CAVEAT Results Further Support Venetoclax Plus Intensive Chemotherapy in Older Patients With AML
The combination regimen of venetoclax plus modified intensive chemotherapy had an acceptable side effect profile and was an effective time-limited regimen for older patients with acute myeloid leukemia ...
